Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and pancreatic cancer, and may offer a substantial improvement over c
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.MarketBeat
- Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDAGlobeNewswire
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.MarketBeat
- Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateGlobeNewswire
MRUS
Earnings
- 5/8/24 - Beat
MRUS
Sec Filings
- 5/10/24 - Form 8-K/A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- MRUS's page on the SEC website